|Ohr Pharmaceutical, Inc.|
489 5th Avenue
United States - Map
OHR Pharmaceutical, Inc. operates as a biotechnology company. Its product line includes Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that inhibits vascular endothelial, platelet derived, and basic fibroblast growth factors for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. The company also offers OHR/AVR 118, a Phase IIa clinical trial product for the treatment of cancer cachexia. In addition, it owns various other compounds in earlier stages of development, including the PTP1b inhibitor trodusquemine and related analogs, which are in preclinical research stage. The company is headquartered in New York, New York.
|Dr. Irach B. Taraporewala B.S., M.S., Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Samuel Backenroth ,
Chief Financial Officer and VP of Bus. Devel.
|Dr. Shalom Z. Hirschman M.D.,
Chief Scientific Advisor
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|